These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 31312198)

  • 1. Lichen Planus Pemphigoides: From Lichenoid Inflammation to Autoantibody-Mediated Blistering.
    Hübner F; Langan EA; Recke A
    Front Immunol; 2019; 10():1389. PubMed ID: 31312198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Challenges and pitfalls between lichen planus pemphigoides and bullous lichen planus.
    Papara C; Danescu S; Sitaru C; Baican A
    Australas J Dermatol; 2022 May; 63(2):165-171. PubMed ID: 35196400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180.
    Zillikens D; Caux F; Mascaro JM; Wesselmann U; Schmidt E; Prost C; Callen JP; Bröcker EB; Diaz LA; Giudice GJ
    J Invest Dermatol; 1999 Jul; 113(1):117-21. PubMed ID: 10417629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lichen Planus Pemphigoides Mimicking Toxic Epidermal Necrolysis.
    Ondhia C; Kaur C; Mee J; Natkunarajah J; Singh M
    Am J Dermatopathol; 2019 Nov; 41(11):e144-e147. PubMed ID: 31145106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lichen planus pemphigoides with predominant mucous membrane involvement: a series of 12 patients and a literature review.
    Combemale L; Bohelay G; Sitbon IY; Ahouach B; Alexandre M; Martin A; Pascal F; Soued I; Doan S; Morin F; Grootenboer-Mignot S; Caux F; Prost-Squarcioni C; Le Roux-Villet C
    Front Immunol; 2024; 15():1243566. PubMed ID: 38686381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of lichen planus pemphigoides with autoantibodies to the NC16a and C-terminal domains of BP180 and to desmoglein-1.
    Sekiya A; Kodera M; Yamaoka T; Iwata Y; Usuda T; Ohzono A; Yasukochi A; Koga H; Ishii N; Hashimoto T
    Br J Dermatol; 2014 Nov; 171(5):1230-5. PubMed ID: 24813536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG autoantibodies from a lichen planus pemphigoides patient recognize the NC16A domain of the bullous pemphigoid antigen 180.
    Skaria M; Salomon D; Jaunin F; Friedli A; Saurat JH; Borradori L
    Dermatology; 1999; 199(3):253-5. PubMed ID: 10592407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bullous lichen planus accompanied by elevation of serum anti-BP180 autoantibody: A possible transitional mechanism to lichen planus pemphigoides.
    Fujii M; Takahashi I; Honma M; Ishida-Yamamoto A
    J Dermatol; 2017 Jun; 44(6):e124-e125. PubMed ID: 28105695
    [No Abstract]   [Full Text] [Related]  

  • 9. Lichen planus pemphigoides induced by a weight reduction drug.
    Rosmaninho A; Sanches M; Oliveira A; Alves R; Selores M
    Cutan Ocul Toxicol; 2011 Dec; 30(4):306-8. PubMed ID: 21428725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cicatricial pemphigoid differs from bullous pemphigoid and pemphigoid gestationis regarding the fine specificity of autoantibodies to the BP180 NC16A domain.
    Kromminga A; Sitaru C; Meyer J; Arndt R; Schmidt E; Christophers E; Bröcker EB; Zillikens D
    J Dermatol Sci; 2002 Jan; 28(1):68-75. PubMed ID: 11916132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab-induced lichen planus pemphigoides in a patient with metastatic non-small-cell lung cancer.
    Senoo H; Kawakami Y; Yokoyama E; Yamasaki O; Morizane S
    J Dermatol; 2020 Apr; 47(4):e121-e122. PubMed ID: 31984550
    [No Abstract]   [Full Text] [Related]  

  • 12. Lichen planus pemphigoides with IgG autoantibodies to the 180 kd bullous pemphigoid antigen (type XVII collagen).
    Hsu S; Ghohestani RF; Uitto J
    J Am Acad Dermatol; 2000 Jan; 42(1 Pt 1):136-41. PubMed ID: 10607335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Childhood lichen planus pemphigoides: a case report and review of the literature.
    Cohen DM; Ben-Amitai D; Feinmesser M; Zvulunov A
    Pediatr Dermatol; 2009; 26(5):569-74. PubMed ID: 19840313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical subacute cutaneous lupus erythematosus presenting as lichen planus pemphigoides with autoantibodies to C-terminus of BP180, desmoglein 1 and SS-A/Ro antigen.
    Inoue Y; Adachi A; Ueno M; Fukumoto T; Nishitani N; Fujiwara N; Yamada Y; Ohyama B; Tsuruta D; Hashimoto T
    J Dermatol; 2012 Nov; 39(11):960-2. PubMed ID: 22413755
    [No Abstract]   [Full Text] [Related]  

  • 15. Lichen planus pemphigoides evolving into pemphigoid nodularis.
    Sakuma-Oyama Y; Powell AM; Albert S; Oyama N; Bhogal BS; Black MM
    Clin Exp Dermatol; 2003 Nov; 28(6):613-6. PubMed ID: 14616828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bullous pemphigoid and related subepidermal autoimmune blistering diseases.
    Olasz EB; Yancey KB
    Curr Dir Autoimmun; 2008; 10():141-66. PubMed ID: 18460884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis.
    Montagnon CM; Tolkachjov SN; Murrell DF; Camilleri MJ; Lehman JS
    J Am Acad Dermatol; 2021 Jul; 85(1):1-14. PubMed ID: 33684496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoreactivity to bullous pemphigoid 180: is this the link between subepidermal blistering diseases and oral lichen planus?
    Shipman AR; Cooper S; Wojnarowska F
    Clin Exp Dermatol; 2011 Apr; 36(3):267-9. PubMed ID: 20569254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab.
    Sato Y; Fujimura T; Mizuashi M; Aiba S
    J Dermatol; 2019 Oct; 46(10):e374-e375. PubMed ID: 31062404
    [No Abstract]   [Full Text] [Related]  

  • 20. BP180 as the common autoantigen in blistering diseases with different clinical phenotypes.
    Zillikens D
    Keio J Med; 2002 Mar; 51(1):21-8. PubMed ID: 11951375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.